Dr Spencer Collis
Clinical Medicine, School of Medicine and Population Health
Reader in Genome Stability
Head of the Genome Stability Group
+44 114 215 9043
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
91直播
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
1994 - 1997
BSc (Hons): Biochemistry, UMIST1997 - 2000
PhD: Oncology, CRUK Paterson Institute for Cancer Research2001 - 2004
Post-Doc: Prof. Theodore DeWeese laboratory, Johns Hopkins University2004 - 2009
Post-Doc: Dr Simon Boulton laboratory, Clare Hall Laboratories, CRUK London Research Institute2009 - 2013
Group leader: Institute for Cancer Studies, University of 91直播2013 - 2015
Senior Lecturer: Academic unit of Molecular Oncology, Department of Oncology, University of 91直播2016 -
Reader: Academic unit of Molecular Oncology, Department of Oncology, University of 91直播Current PhD Opportunities:
- Research interests
-
The overarching research goals of the Collis laboratory is to identify and functionally characterise novel factors that are important for the maintenance of genome integrity in human cells. This research also aims to establish if such factors are novel drug targets and/or biomarkers that can be exploited to improve the treatment of diseases such as cancer, either alone, or in combination with existing chemo- and/or radio-therapeutic regimes. To achieve this, the Collis group collaborate with a range of national and international scientists and clinicians to maximise the potential therapeutic impact of their basic biological discoveries.
Funding Sources
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Cancers, 16(5).
- . F1000Research, 12.
- . British Journal of Cancer.
- . Expert Reviews in Molecular Medicine, 24.
- . Molecular Oncology, 16(1), 11-41.
- . Cancers, 13(5).
- . Br J Cancer, 124(4), 697-709.
- . Sci Adv, 6(28), eaba5974.
- . Cancers (Basel), 11(3).
- . Oncotarget, 9(50), 29508-29524.
- . Sci Rep, 6, 35548.
- . Nucleic Acids Res, 44(18), 8772-8785.
- . Cell Rep, 16(10), 2565-2575.
- . Cilia, 5, 19.
- . Cell Cycle, 13(21), 3450-3459.
- . Oncotarget, 5(15), 6414-6424.
- . J Cell Sci, 127(Pt 13), 2910-2919.
- . J Cell Sci, 125(Pt 20), 4770-4779.
- . F1000Research, 13, 1316-1316.
All publications
Journal articles
- . Neuro-Oncology, 26(Supplement_8), viii118-viii118.
- . Neuro-Oncology, 26(Supplement_8), viii117-viii118.
- . Cancers, 16(5).
- . F1000Research, 12.
- . Neuro-Oncology, noad210.
- . British Journal of Cancer.
- . Neuro-Oncology, 25(Supplement_3), iii14-iii14.
- . Nanotheranostics, 7(1), 102-116.
- . Neuro-Oncology, 24(Supplement_7), vii31-vii31.
- . Neuro-Oncology, 24(Supplement_7), vii93-vii93.
- . Expert Reviews in Molecular Medicine, 24.
- . Molecular Oncology, 16(1), 11-41.
- . BRITISH JOURNAL OF CANCER, 125(4), 623-623.
- . British Journal of Surgery, 108(Supplement_1).
- . Cancers, 13(5).
- . Br J Cancer, 124(4), 697-709.
- . Sci Adv, 6(28), eaba5974.
- . J Cell Sci, 133(9).
- . Neuro-Oncology, 21(Supplement_6), vi209-vi209.
- . Neuro-Oncology, 21(Supplement_6), vi271-vi271.
- . Cancers (Basel), 11(3).
- NOVEL DRUG TARGETS TO AUGMENT TEMOZOLOMIDE SENSITIVITY IN HIGH-GRADE BRAIN TUMOURS. NEURO-ONCOLOGY, 20, 346-346.
- . Neuro-Oncology, 20(suppl_3), iii297-iii297.
- . Oncotarget, 9(50), 29508-29524.
- . Sci Rep, 6, 35548.
- . Nucleic Acids Res, 44(18), 8772-8785.
- . Cell Rep, 16(10), 2565-2575.
- . Cilia, 5, 19.
- . Neuro-Oncology, 17(suppl 8), viii20.1-viii20.
- . Cell Cycle, 13(21), 3450-3459.
- . Oncotarget, 5(15), 6414-6424.
- . J Cell Sci, 127(Pt 13), 2910-2919.
- . Development, 140(2), e207-e207.
- . J Cell Sci, 125(Pt 20), 4770-4779.
- . Mol Cell, 39(6), 839-850.
- . Mol Cell, 39(1), 25-35.
- . PLoS One, 5(6), e11208.
- . EMBO J, 29(4), 703-705.
- . Cell Cycle, 8(8), 1133-1137.
- . Mol Cell Biol, 28(5), 1470-1479.
- . Mol Cell, 32(3), 313-324.
- . Cell, 135(2), 261-271.
- . Int J Radiat Oncol Biol Phys, 70(5), 1310-1318.
- . Int J Radiat Oncol Biol Phys, 69(4), 1262-1271.
- . Chromosoma, 116(4), 331-339.
- . Nat Cell Biol, 9(4), 391-401.
- . CANCER RES, 66(17), 8814-8821.
- . DNA Repair (Amst), 5(11), 1398-1406.
- . Oncogene, 24(6), 949-961.
- . J Biol Chem, 279(48), 49624-49632.
- . Cancer Metastasis Rev, 23(3-4), 277-292.
- . Radiat Res, 162(1), 48-55.
- . Radiat Res, 161(3), 247-255.
- . World J Urol, 21(4), 275-289.
- Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.. Cancer Res, 63(7), 1550-1554.
- Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.. Int J Radiat Biol, 79(1), 53-60.
- . Nucleic Acids Res, 30(2), E1.
- . Nucleic Acids Res, 29(7), 1534-1538.
- . Cell Death & Disease, 15(12).
- . F1000Research, 13, 1316-1316.
- . F1000Research, 12, 954-954.
Chapters
- , Targeted Radionuclide Tumor Therapy: Biological Aspects (pp. 329-347).
- Molecular targeting of DNA repair: A means to improve therapeutic index, New Research on DNA Repair (pp. 1-37).
Conference proceedings papers
- . Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
- . Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022.
- . WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- FA-BASED COMBINATIONS TO TARGET THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 20 (pp 358-358)
- PRECLINICAL EVALUATION OF COMBINATIONS TARGETING THE DNA DAMAGE RESPONSE IN 2D AND 3D MODELS OF GLIOBLASTOMA STEM CELLS. NEURO-ONCOLOGY, Vol. 20 (pp 297-297)
- Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 96(2) (pp E566-E567). Boston, Massachusetts, USA
- IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. NEURO-ONCOLOGY, Vol. 17 (pp 20-20)
- Optimization of siRNA-transgene expression in adenoviral vector systems for radiation sensitizing strategies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 69(3) (pp S595-S596)
- . BREAST CANCER RESEARCH, Vol. 8 (pp S6-S6)
Preprints
- Research group
-
Research Group
- Dr. Katie Myers (Research Assistant/Lab Manager)
- Dr. Callum Jones (Postdoctoral Research Associate)
- Dr. Nikita Lad (Postdoctoral Research Associate)
- Dr. Sophie Williams (Clinical PhD Fellow)
- Connor McGarrity-Cottrell (PhD student)
- Hannah Gagg (PhD student with Dr. Greg Wells and Mr. Ola Rominiyi)
- Kelsey Wosnitzka (PhD student with Mr. Ola Rominiyi)
- Rebecca Livesey (PhD student with Prof. Fred Claeyssens)
- Tegan Torpey (PhD student with Mr. Ola Rominiyi and Prof. Fred Claeyssens)
- Teaching interests
-
M.Sc. Molecular Medicine
M.Sc. Translational Oncology
MSc Genomic Medicine